Anaplastic thyroid cancer (ATC) is a rare malignancy but is one of the most fatal human cancers. There are no standard or effective therapies for locally advanced and metastatic ATC and most patients localized ATC develop recurrence. We performed an integrated genome-wide expression analysis and high-throughput drug screening in ATC.
Introduction
Anaplastic (undifferentiated) thyroid cancer (ATC) has an incidence of approximately 1 to 2 cases per million per year (1, 2) . However, patients with ATC have a median survival time of less than 6 months, with fewer than 20% of patients surviving one year. Because ATC, although rare, is a lethal malignancy, accounting for approximately one-third of all thyroid cancer-related deaths (2) (3) (4) , there is a pressing need for new effective therapies.
Traditional approaches to drug discovery require a significant investment of time and funding. The drug development process is further limited by the declining number of new active substances entering development phases, as well as by the persistently high rate of late-stage drug failures (5) . An emerging approach to developing therapies for rare, or orphan, cancers such as ATC instead exploits the multitude of established compounds, which are already approved for clinical use or currently in clinical trials (6) (7) (8) . Recycling these established agents for new indications is an attractive approach for several reasons. Given that repurposed compounds have known pharmacokinetic, pharmacodynamic, and toxicity profiles, promising drugs can be rapidly transitioned into phase II or phase III clinical trials to test efficacy. Furthermore, profiling drugs may also help to uncover new insights into the processes underlying carcinogenesis as well as aid in identifying novel cancer-specific targets for therapy.
In this study, we undertook a quantitative high-throughput screening (qHTS) 
Materials and Methods

Cell Lines and Animals
Human ATC cell line 8505C was purchased from the European Collection of Cell Cultures (United Kingdom), and cell lines C643 and SW1736 were purchased from CLS Cell Lines Service GmbH (Germany). The human thyroid cancer cell lines THJ-16T, THJ-21T and THJ-29T were a kind gift from Dr. John A. Copland (Mayo Clinic). The ATC cell lines were maintained in Dulbecco's Modified Eagle Medium (DMEM) with 4,500 mg/L D-glucose, 2 mM L-glutamine, and 110 mg/L sodium pyruvate, supplemented with 10% fetal bovine serum (FBS), penicillin (10,000 U/mL), streptomycin (10,000 U/mL), and fungizone (250 mg/mL), in a standard humidified incubator at 37°C, in a 5% CO 2 atmosphere. The cell lines were authenticated using short tandem repeat profiling. Six-to eight-week-old NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ breeder mice were purchased from the Jackson Laboratory. The mice were maintained and bred according to the guidelines of the NIH Animal Research Advisory Committee (ARAC).
National Institutes of Health Chemical Genomics Center pharmaceutical library screening
The National Institutes of Health Chemical Genomics Center Pharmaceutical Collection (NPC) and the Mechanism Interrogation PlatE (MIPE) collection consists of 3,282 small-molecule compounds and drugs approved for human or animal use.
Test compounds from the library were prepared as previously described (9) .
Quantitative high-throughput proliferation assay
Cell viability after compound treatment was measured using a luciferase-coupled ATP quantitation assay (CellTiter-Glo) in 8505C, C643, and SW1736 cells. The change 
Survivin expression analysis in thyroid tissue
The dataset GSE29265, with 49 thyroid samples, was downloaded from the National Center for Biotechnology Information Gene Expression Omnibus (GEO) database (GSE29265). There were 20 normal samples, 20 papillary thyroid cancers (PTCs), and 9 ATCs in this dataset. Normalized intensity values for survivin, also known as BIRC5 (probeset ID X202094_at, X202095_s_at, and X210334_x_at), were extracted for analysis and adjusted for multiple comparison.
Independent thyroid tissue samples for immunohistochemistry were used to evaluate survivin protein expression. Tissue microarrays were purchased from US Biomax (#TH641). This array contained duplicates of 6 follicular adenomas, 6 follicular thyroid carcinomas, 6 PTCs, and 6 ATCs, as well as 16 normal tissues from lungs, thyroid, and testis.
Cell proliferation
Cell proliferation assays were performed in quadruplicates, with 8505C, SW1736, cell densities were determined using a 96-well fluorescence microplate reader (Molecular Devices) at 485 nm/538 nm.
Western blot
The total protein lysate was analyzed by SDS/PAGE, transferred to a nitrocellulose membrane, and immunostained overnight at 4°C with the following antibodies: anti-survivin (1:250, Cell Signaling Technology); anti-GAPDH (1:3000, Santa Cruz Biotechnology); anti-claspin (1 μg/mL, R&D Systems, Inc); anti-β-actin (1:3000, Santa Cruz Biotechnology). GAPDH and β-actin were used as a loading control.
The membranes were incubated with the appropriate horseradish peroxidase-conjugated IgG (anti-rabbit 1:3000, Cell Signaling Technology, or anti-mouse 1:10000, Santa Cruz Biotechnology), and proteins were detected by enhanced chemiluminescence (ECL; Thermo Scientific).
Immunohistochemistry
To examine the protein expression of survivin, immunohistochemistry was performed using a tissue array TH641 (US Biomax, Inc) with a rabbit polyclonal antibody (Novus Biologicals, NB500-201) at 1:500 dilution. Briefly, slides were deparaffinized in xylene and graded alcohols, and subjected to antigen retrieval in a pressure cooker with citrate buffer (pH6) for 20 minutes. Endogenous enzyme activity was blocked with 3% hydrogen peroxide in methanol with additional serum-free protein blocking to reduce nonspecific reactions. Subsequently, slides were incubated with primary antibody for 60 minutes at room temperature, and antigen-antibody reaction was 
Cell cycle assay
Cells were plated in 6-well plates at 6 × 10 hours and 48 hours, the cells were harvested, fixed with cold 70% ethanol for 30 minutes at 4°C, and incubated in the dark with RNase (100 mg/mL) and propidium iodide (50 mg/mL) for 30 minutes at 37°C. A total of 20,000 nuclei were examined by flow cytometry using a Calibur flow cytometer (Becton/Dickinson), and data were analyzed using ModFit software (Verity Software House).
Small interfering (si)RNA transfection
The siRNA for human Claspin (siRNA ID: s34330 and s34331) and scrambled 
Statistical analysis
To determine compound activity in the qHTS assay, raw plate reads for each titration point were first normalized to a positive control (tetraoctylammonium bromide, a toxin, 100% inhibition) and DMSO-only wells (0% inhibition). The titration-response 
Results
Identification of YM155 as an active agent in ATC cells
We identified 100 active compounds in the three ATC cell lines (8505C, C643, and SW1736). One of the most active compounds with high efficacy and low IC 50 was YM155 (Fig. 1A, Table 1 ). YM155 had an efficacy greater than 90% in all three ATC cell lines and an IC 50 in the nanomolar range. The IC 50 in the ATC cell lines was well below that achieved in humans (11) . The ATC cells had greater sensitivity to YM155 than to the therapeutic agents previously used in the clinic (Fig. 1B) (12-14) .
Survivin is overexpressed in human thyroid cancer (including ATC) and ATC cell lines
YM155 is a first-in-class suppressant of survivin. Consequently, we sought to determine whether survivin is in fact overexpressed in thyroid cancer. We first used samples from the publically available GEO database (GSE29265) to examine mRNA expression levels of survivin in ATC, PTC, and normal thyroid tissue. Survivin was significantly upregulated in ATC as compared to PTC and normal thyroid tissue (p < 0.01), and the ATC samples clustered together (Fig. 1C) . We next evaluated survivin protein expression in an independent set of thyroid tissue samples (Fig. 1D) . Survivin protein expression was positive in all ATC and PTC samples, in 3 of 6 follicular thyroid cancer samples, and no follicular adenomas or normal thyroid tissue samples. Two of the 6 ATC samples had nuclear staining in addition to cytoplasmic staining (Fig. 1D) .
Western blot analysis of survivin expression in ATC cell lines revealed abundant survivin expression levels ( Fig. 2A) .
Research. 
YM155 inhibits cell proliferation, reduces survivin and claspin expression, and arrests cells in S phase
Given the activity of YM155 in the qHTS assay and the overexpression of its target in thyroid cancer, especially ATC, we next validated the antiproliferative effect of YM155 in 6 ATC cell lines. Treatment with YM155 inhibited cellular proliferation in all ATC cell lines tested, and this response was found to be dose-and time-dependent (Fig.   2B ). YM155 treatment reduced survivin expression in all ATC cell lines (Fig. 2C) .
Interestingly, YM155 treatment in 6 of the ATC cell lines had no significant effect on caspase 3/7 activity (3-8 nM vs. vehicle for 12-72 hours, data not shown). Thus, we evaluated cell morphology with YM155 treatment and also found increased LC3B expression, a marker of autophagy, with YM155 treatment (Fig. 3A and 3B) (15, 16) . To further determine the mechanism by which YM155 inhibited cellular proliferation, we analyzed key proteins involved in regulating apoptosis using a human apoptosis array. In addition to inhibiting survivin expression and increasing LC3B expression, YM155 reduced claspin expression in ATC cells (Fig. 3C) . The reduced expression of claspin was confirmed by Western blot analysis (Fig. 3D) . Because claspin regulates DNA replication in normal cells, we performed cell cycle analysis on the ATC cells after YM155 treatment (3-8 nM vs. vehicle) (17, 18) . YM155 treatment increased the number of cells in S phase (by 14-34%) and decreased the number of cells in G 0 G 1 in the ATC cell lines tested (8505C, C643, and SW1736) (Fig. 4A) . To determine if the effect of YM155 on reduced claspin expression may mediate the effect of YM155 on cellular proliferation and cell cycle, we directly knocked down the expression of claspin in ATC cell lines (8505C, C643, and SW1736) (Fig. 4B) . Claspin knockdown in ATC cells 
YM155 induces significant regression of metastatic tumor burden and prolongs survival in vivo
We further validated the antitumor activity of YM155 in an in vivo ATC metastases mouse model, which is a clinically relevant model for human ATC.
Following 4 weeks of treatment, mice receiving YM155 at 2 mg/kg showed tumor growth inhibition, and, in some mice, regression of metastatic tumor burden was observed (Fig. 5A ). This significant antitumor effect was observed after only 1 week of treatment, with sustained activity over the remaining treatment period. We then validated these results in an independent experiment at 5 weeks, 1 week after treatment was stopped, and observed significant growth inhibition (Fig. 5B) . There was no significant difference between the treated and untreated mice in weight change, and no serious adverse effects were observed during the treatment period. The overall survival of mice treated with YM155 was significantly longer, as compared to the control, with a mean survival of 42 days for the control group and 89 days for YM155-treated mice (Fig. 5C ).
As shown in Fig. 5D , the animal life spans were significantly increased in the treatment group, even after stopping YM155 treatment. 
Discussion
In this study, we used qHTS to identify YM155, the first-in-class agent that targets survivin, as an active agent against ATC cells. We found significant overexpression of survivin in ATC, PTC, and follicular thyroid cancer, as compared with benign thyroid tumors and normal thyroid tissue. We validated the potent dose-and timedependent effect that YM155 has on growth in vitro, and on metastases and survival in an ATC metastatic mouse model. In addition to inhibiting survivin expression in ATC cells, YM155 also reduced claspin expression, which was associated with an increased number of cells in S phase. Together, these findings support the use of YM155 as a novel therapeutic option in locally advanced and metastatic ATC.
YM155 is a first-in-class survivin inhibitor currently in phase I/II clinical trials as monotherapy or combination therapy for a variety of human malignancies (11, (19) (20) (21) (22) (23) .
Our qHTS in ATC cell lines revealed that YM155 was one of the most active therapeutic agents, with an IC 50 10-fold lower than the C max from phase I clinical trials. Furthermore, delivery of YM155 by continuous infusion (24) presented many additional advantages, widening the therapeutic window of the drug and avoiding the excessive fluctuations in plasma levels that either produce unwanted side effects or result in subtherapeutic levels (25, 26) . Finally, screening data that compared the antiproliferative effects of YM155 with chemotherapeutic agents used in patients with ATC, doxorubicin and docetaxel, showed greater efficacy of YM155 at much lower drug concentrations. 
YM155 reduces survivin expression is unclear, it is believed to target the promoter region of the survivin gene, BIRC5, suppressing expression at both the mRNA and protein levels (24) . Furthermore, YM155 has been shown to selectively suppress survivin, with little effect on the expression levels of other apoptosis-related proteins (24) . Using an apoptosis protein array, we also found YM155 treatment produced no significant variation in anti-and pro-apoptosis proteins. Survivin is known to associate with microtubules of the mitotic spindle at the beginning of mitosis, serving as an important regulator of cell cycle progression (27) . Furthermore, disruption of survivin-microtubule interactions has been shown to induce cell cycle arrest, apoptosis, and subsequent cell death (28) . Several studies have shown that survivin is upregulated in ATC and is associated with more aggressive thyroid cancer (29, 30) . Claspin is required for efficient DNA replication during normal S phase and is highly expressed in more aggressive cancers (17, (31) (32) (33) . YM155 treatment did affect cell morphology in ATC cells and increased LC3B expressing consistent with its effect on autophagy in other cancer cells groups in the amount of weight lost, and no adverse effects were observed in the test group. A longer survival time was also observed in the treatment group, even after withdrawal of YM155 treatment. These findings suggest that YM155 would be an effective anticancer agent for locally advanced and metastatic ATC in humans.
In conclusion, we identified the first-in-class survivin suppressant, YM155, as an active agent in ATC cells, using qHTS. We confirmed that YM155 exhibits strong antitumor activity against human ATC cells in vitro and validated its antitumor activity in vivo, using a metastasis mouse model that recapitulates the clinical features of ATC.
Moreover, we found that survivin was overexpressed in ATC, making it an attractive target for ATC therapy and one to be considered for clinical trials.
